Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to the Accrax Pharmaceutical third quarter 2025 conference call and business update. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Robert Shaw, Chief Financial Officer. Thank you, sir. You may begin. Thank you, Maria. Good morning and welcome to our call. This morning we issued a press release providing financial results and company highlights for the third quarter of 2025, which is available on our website at accorexpharma.com. Joining me today is Dave Lucci, President and CEO of Accorex, who will give a corporate update and outlook. Following that, I'll provide some highlights of the financials from the third quarter ended September 30, 2025, and then turn the call back over to Dave for his closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements, which are based on current information, assumptions, estimates, and projections about future events that are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Investors should consider these risks and other information described in our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed today, Wednesday, November 12, 2025. You are cautioned not to place undue reliance on these forward-looking statements And ACRx disclaims any obligation to update such statements at any time in the future. Th...